Results 201 to 210 of about 2,459,862 (252)
Some of the next articles are maybe not open access.
Hematology/Oncology Clinics of North America, 1992
The general characteristics of antithrombin III (AT III) concentrates available in the United States are described in this article. The effectiveness of AT III concentrates in the prevention and treatment of thrombotic episodes in patients with hereditary AT III deficiency are summarized, and the use of this product in various conditions with acquired ...
openaire +2 more sources
The general characteristics of antithrombin III (AT III) concentrates available in the United States are described in this article. The effectiveness of AT III concentrates in the prevention and treatment of thrombotic episodes in patients with hereditary AT III deficiency are summarized, and the use of this product in various conditions with acquired ...
openaire +2 more sources
Blood Reviews, 1988
A moderate reduction of plasma antithrombin activity is an uncommon but clinically important cause of severe thromboembolic disease. In recent years the molecule responsible for the major part of this activity (antithrombin III) has been extensively characterised and the mode of inheritance of familial deficiencies worked out.
openaire +2 more sources
A moderate reduction of plasma antithrombin activity is an uncommon but clinically important cause of severe thromboembolic disease. In recent years the molecule responsible for the major part of this activity (antithrombin III) has been extensively characterised and the mode of inheritance of familial deficiencies worked out.
openaire +2 more sources
Scandinavian Journal of Urology and Nephrology, 1979
Antithrombin III (AT-III) was measured immunologically in 20 uremic patients on maintenance hemodialysis and in 10 non-dialysed uremic patients. The dialysed patients had slightly elevated AT-III levels. The non-dialysed patients had significantly elevated AT-III levels.
K A, Jørgensen, E, Stoffersen
openaire +2 more sources
Antithrombin III (AT-III) was measured immunologically in 20 uremic patients on maintenance hemodialysis and in 10 non-dialysed uremic patients. The dialysed patients had slightly elevated AT-III levels. The non-dialysed patients had significantly elevated AT-III levels.
K A, Jørgensen, E, Stoffersen
openaire +2 more sources
A new familial variant of antithrombin III: ‘Antithrombin III Paris’
British Journal of Haematology, 1982Summary. A 59‐year‐old woman presented a recurrent history of thromboembolism. A qualitative defect of antithrombin III (AT III) was suggested by the discrepancy between a normal amount of AT III antigen and a decreased heparin cofactor activity. Six members of the same family showed a similar defect although clinically asymptomatic.
M, Wolf +3 more
openaire +2 more sources
Antithrombin III I. Evaluation of an automated antithrombin III method
Thrombosis Research, 1978Abstract An automated method for the determination of antithrombin III activity (as heparin cofactor activity) is described using the chromogenic substrate Chromozym® TH. A linear relationship is obtained between 10–160% of the AT-III activity of normal plasma and there are good correlations with both antigen level as well as with progressive ...
L H, Kahlé +3 more
openaire +2 more sources
Congenital antithrombin III deficient neonate treated with antithrombin III concentrates
Thrombosis Research, 1993A patient with antithrombin III deficiency developed deep vein thrombosis during her first pregnancy. Her pregnancy and delivery were successfully treated with simultaneous administration of antithrombin III concentrates and low molecular weight heparin. She delivered a 2,412g girl at 39 weeks' gestation. The baby was administered with antithrombin III
A, Shiozaki +4 more
openaire +2 more sources
Safety of virus inactivated antithrombin III concentrate ANTITHROMBIN III IMMUNO (AT III)
Thrombosis Research, 1992In a prospective clinical trial the risk of infection after application of virus inactivated antithrombin III concentrate ANTITHROMBIN III IMMUNO (AT III) was investigated in patients undergoing cardiovascular surgery. The study was conducted according to the recommendations of the International Committee on Thrombosis and Hemostasis (ICTH), with the ...
D U, Preiss +3 more
openaire +2 more sources
Thrombin-Antithrombin III Complexes and Antithrombin III in Amniotic Fluid
Gynecologic and Obstetric Investigation, 1997We measured thrombin-antithrombin III (TAT) complexes and antithrombin III (AT III) in amniotic fluid and blood plasma of 39 parturient women. TAT was measured by ELISA. Partigen plates were used for measuring the antigen of AT III, and activity was determined using chromogenic substrate.
M, Uszyński +3 more
openaire +2 more sources
Neonatal antithrombin III deficiency
The American Journal of Medicine, 1989Hemorrhagic and thrombotic complications are common in sick preterm infants and may reflect inadequate regulation of coagulation. All neonates have low levels of the pivotal regulator antithrombin III (ATIII) compared with adults. Plasma levels of ATIII are very low in preterm infants and are further diminished in infants with respiratory distress ...
openaire +2 more sources
Sneddon's Syndrome and Antithrombin III
The Journal of Dermatology, 1999AbstractSneddon's syndrome, an uncommon disorder, is characterized by multiple cerebrovascular accidents along with ideopathic livedo reticularis. In this article, two cases who had increased amounts of antithrombin III and were diagnosed with Sneddon's syndrome are presented.
Bolayir E. +4 more
openaire +4 more sources